Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-08044-5 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Alessandro Bertocchi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy. alessandro.bertocchi@st.hun…. Hauptthemen laut MEDLINE: Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Positron-Emission Tomography. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Testicular germ cell tumours (TGCTs) are the most common malignancy in young adult males. After chemotherapy, the evaluation of residual masses is critical. However, the current standard imaging modality, [ 18 F]-FDG PET, has limited specificity—particularly in distinguishing viable tumour from necrosis or mature teratoma. This limitation often leads to unnecessary surgery or misinterpretation of treatment response.
Objectives
This systematic review aims to explore and evaluate novel PET tracers that could improve diagnostic accuracy in TGCTs, especially in post-chemotherapy settings.
Methods
A comprehensive literature search was conducted on PubMed and Scopus through December 2025, using terms including “testicular,” “germ cell tumour,” “PET scan,” and “novel.” Studies focusing solely on [ 18 F]-FDG were excluded. Preclinical studies, case reports, and clinical trials investigating alternative PET tracers or relevant molecular targets (e.g., ghrelin, claudin-6) were included. The quality of selected articles was assessed by using CASP for the qualitative research.
Results
A total of 17 studies met the inclusion criteria. Emerging PET tracers evaluated include [ 18 F]-FLT, FAPI, αvβ3-integrin-targeted agents, [ 18 F]-fluciclovine, PSMA-targeted tracers, and those based on ghrelin and claudin-6. Among these, αvβ3-targeted imaging has shown promising preclinical results in differentiating mature teratoma from necrosis. Ghrelin receptor tracers appear promising due to their high expression in TGCTs, although they remain in preclinical development. Claudin-6, a tight-junction protein, is highly expressed in most TGCT histologies and may be a viable molecular target, as supported by early-phase clinical trials.
Conclusions
Novel PET tracers represent a promising avenue to refine TGCT management. αvβ3-integrin and ghrelin-based tracers are particularly noteworthy for their potential to guide decision-making after chemotherapy. However, further clinical validation is required before routine implementation. These innovations could significantly reduce overtreatment and enhance personalized care in TGCT patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy. alessandro.bertocchi@st.hunimed.eu.
- Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy. alessandro.bertocchi@st.hunimed.eu.
- Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy. fabio.de_vincenzo@humanitas.it.
- Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.
- Nuclear Medicine Unit, Humanitas Gavazzeni, Via Mauro Gavazzeni 21, 24125, Bergamo, Italy.
Zitieren
APA
Bertocchi, A., De Vincenzo, F., Perrino, M., Cordua, N., Guglielmo, P., Aliprandi, M., Cecchi, L. G., Federico, A., Panzardi, A., Santoro, A., Evangelista, L., & Zucali, P. A. (2026). Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08044-5
Vancouver
Bertocchi A, De Vincenzo F, Perrino M, Cordua N, Guglielmo P, Aliprandi M, et al. Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08044-5
BibTeX
@article{Bertocchi2026,
author = {Bertocchi, Alessandro and De Vincenzo, Fabio and Perrino, Matteo and Cordua, Nadia and Guglielmo, Priscilla and Aliprandi, Marta and Cecchi, Luigi Giovanni and Federico, Antonio and Panzardi, Antonella and Santoro, Armando and Evangelista, Laura and Zucali, Paolo Andrea},
title = {Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-08044-5}
}
EUVIMED